tetano
Editor, Senior Moderator
Vaccine. 2019 Aug 21. pii: S0264-410X(19)31074-6. doi: 10.1016/j.vaccine.2019.08.024. [Epub ahead of print]
[h=1]Comparison of vaccine effectiveness against influenza hospitalization of cell-based and egg-based influenza vaccines, 2017-2018.[/h] Bruxvoort KJ[SUP]1[/SUP], Luo Y[SUP]2[/SUP], Ackerson B[SUP]3[/SUP], Tanenbaum HC[SUP]4[/SUP], Sy LS[SUP]5[/SUP], Gandhi A[SUP]6[/SUP], Tseng HF[SUP]7[/SUP].
[h=3]Author information[/h] 1 Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: katia.bruxvoort@kp.org. 2 Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Yi.X.Luo@kp.org. 3 Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Bradley.K.Ackerson@kp.org. 4 Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Hilary.Tanenbaum@kp.org. 5 Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Lina.S.Sy@kp.org. 6 Seqirus, Summit, NJ, United States. Electronic address: Ashesh.Gandhi@Seqirus.com. 7 Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Hung-Fu.X.Tseng@kp.org.
[h=3]Abstract[/h] Egg-based influenza vaccines could be less effective than cell-based vaccine due to adaptive mutations acquired for growth. We conducted a test-negative case-control study at Kaiser Permanente Southern California to assess vaccine effectiveness (VE) against hospitalization for laboratory-confirmed influenza during 2017-2018. Among the 1186 cases and 6946 controls, 74% and 59%, respectively, were ages ≥ 65 years. For any influenza, the adjusted relative VE of cell-based vaccine versus egg-based vaccines was 43% (95% CI: -45% to 77%) for patients ages < 65 years and 6% (95% CI: -46% to 39%) for patients ages ≥ 65 years. For influenza A(H3N2), the adjusted relative VE was 61% (95% CI: -63% to 91%) for patients ages < 65 years and -4% (95% CI: -70% to 37%) for patients ages ≥ 65 years. Statistically significant protection against influenza hospitalization of cell-based vaccine compared to egg-based vaccines was not observed, but further studies in additional influenza seasons are warranted.
Copyright ? 2019. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Influenza; Influenza vaccine; Vaccine effectiveness
PMID: 31445771 DOI: 10.1016/j.vaccine.2019.08.024
[h=1]Comparison of vaccine effectiveness against influenza hospitalization of cell-based and egg-based influenza vaccines, 2017-2018.[/h] Bruxvoort KJ[SUP]1[/SUP], Luo Y[SUP]2[/SUP], Ackerson B[SUP]3[/SUP], Tanenbaum HC[SUP]4[/SUP], Sy LS[SUP]5[/SUP], Gandhi A[SUP]6[/SUP], Tseng HF[SUP]7[/SUP].
[h=3]Author information[/h] 1 Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: katia.bruxvoort@kp.org. 2 Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Yi.X.Luo@kp.org. 3 Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Bradley.K.Ackerson@kp.org. 4 Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Hilary.Tanenbaum@kp.org. 5 Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Lina.S.Sy@kp.org. 6 Seqirus, Summit, NJ, United States. Electronic address: Ashesh.Gandhi@Seqirus.com. 7 Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Hung-Fu.X.Tseng@kp.org.
[h=3]Abstract[/h] Egg-based influenza vaccines could be less effective than cell-based vaccine due to adaptive mutations acquired for growth. We conducted a test-negative case-control study at Kaiser Permanente Southern California to assess vaccine effectiveness (VE) against hospitalization for laboratory-confirmed influenza during 2017-2018. Among the 1186 cases and 6946 controls, 74% and 59%, respectively, were ages ≥ 65 years. For any influenza, the adjusted relative VE of cell-based vaccine versus egg-based vaccines was 43% (95% CI: -45% to 77%) for patients ages < 65 years and 6% (95% CI: -46% to 39%) for patients ages ≥ 65 years. For influenza A(H3N2), the adjusted relative VE was 61% (95% CI: -63% to 91%) for patients ages < 65 years and -4% (95% CI: -70% to 37%) for patients ages ≥ 65 years. Statistically significant protection against influenza hospitalization of cell-based vaccine compared to egg-based vaccines was not observed, but further studies in additional influenza seasons are warranted.
Copyright ? 2019. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Influenza; Influenza vaccine; Vaccine effectiveness
PMID: 31445771 DOI: 10.1016/j.vaccine.2019.08.024